Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph + Acute Lymphoblastic Leukemia

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL) is currently treated with BCR-ABL1 tyrosine kinase inhibitors (TKI) in combination with chemotherapy. However, most patients develop resistance to TKI through BCR-ABL1-dependent and -independent mechanisms. Newly developed TKI ca...

Full description

Bibliographic Details

Published in:	Cancer research (Chicago, Ill.) Vol. 78; no. 4; p. 1097
Main Authors:	De Dominici, Marco, Porazzi, Patrizia, Soliera, Angela Rachele, Mariani, Samanta A, Addya, Sankar, Fortina, Paolo, Peterson, Luke F, Spinelli, Orietta, Rambaldi, Alessandro, Martinelli, Giovanni, Ferrari, Anna, Iacobucci, Ilaria, Calabretta, Bruno
Format:	Journal Article
Language:	English
Published:	United States 15.02.2018
Subjects:	Animals Cyclin-Dependent Kinase 6 - genetics Cyclin-Dependent Kinase 6 - metabolism Humans Mice Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Proto-Oncogene Proteins c-bcl-2 - genetics Proto-Oncogene Proteins c-bcl-2 - metabolism
ISSN:	1538-7445, 1538-7445
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!